Panasonic Set for R...
Health Care: Drugs
Vertex Pharmaceuticals (VRTX: NASDAQ)
$36.78 -1.60 | -4.17%
02/03/12 - 04:00 PM ET
8.26M / 3.50M
Vol / Avg. Vol:37.54 / 38.38
Open / Prev. Close:35.43 - 38.10
Today's Range:26.50 - 58.87
52 Wk Range:10.75%
Performance YTD:TheStreet Rating:
Portfolios with VRTX
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
- Contributor10 Hep C Stocks on Wall Str...
- ContributorBreakout Stocks Of The Week...
- Contributor11 Biotech Stocks Loved or ...
- ContributorTechnical Setups for the We...
- Contributor5 Biotech Drug-Launch Stock...
- ContributorHot Biotech Trades for Seco...
- UserStocks to Track
- Contributor3 Top Funds' Best Stock Picks
Latest VRTX Headlines from TheStreet
- Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance 02.03.12 | 07:02 am
- Vertex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript 02.02.12 | 11:02 pm
- Drugmakers Singing Same Song: 2012 Will Be Tough 02.02.12 | 04:02 pm
- Business Highlights 01.31.12 | 06:01 pm
- Vertex Wins Early Approval of Cystic Fibrosis Drug 01.31.12 | 01:01 pm
- Vertex Hep C Sales Growth Nears End 01.31.12 | 06:01 am
- Vertex Pharmaceuticals' CEO Presents At JPMorgan Global Healthcare Conference (Transcript) 01.09.12 | 07:01 pm
- Hep C Takeover Speculation Rains Down on Idenix and Achillion 01.08.12 | 01:01 pm
- Biotech Buyside Predictions for 2012 01.05.12 | 09:01 am
- Ring In New Year With Broadcom, Vertex
12.30.11 | 06:12 am
Press Releases for VRTX
- Vertex Reports Fourth Quarter And Full-Year 2011 Financial Results - Business Wire 02.02.12 | 04:02 pm
- KALYDECO Logo (Graphic: Business Wire) - Business Wire 01.31.12 | 11:01 am
- Vertex Announces The Date Of Its Full Year 2011 Financial Results Conference Call And Webcast - Business Wire 01.17.12 | 09:01 am
- Vertex Announces Key 2012 Business Objectives As Company Prepares For Planned Global Launch Of KALYDECO In Cystic Fibrosis - Business Wire 01.08.12 | 08:01 pm
- Vertex Announces Webcast Of Its Presentation At The 30th Annual J.P. Morgan Healthcare Conference - Business Wire 01.04.12 | 09:01 am
- FDA Grants Priority Review For KALYDECO™ (ivacaftor), The First Potential Medicine To Target The Underlying Cause Of Cystic Fibrosis - Business Wire 12.15.11 | 07:12 am
- Jeffrey Leiden, M.D., Ph.D. (Photo: Business Wire) - Business Wire 12.15.11 | 07:12 am
- Vertex And Alios BioPharma Begin Clinical Studies Of Nucleotide Drug Candidates ALS-2200 And ALS-2158 For The Treatment Of Hepatitis C - Business Wire 12.09.11 | 08:12 am
- Vertex Pharmaceuticals Announces Webcast Of Its Presentation At The 23rd Annual Piper Jaffray Health Care Conference - Business Wire 11.22.11 | 04:11 pm
- Phase 2 Data For Selective Oral JAK3 Inhibitor VX-509 Show Significant Improvements In Signs And Symptoms Of Rheumatoid Arthritis - Business Wire 11.05.11 | 05:11 pm
Partner Headlines for VRTX
- Vertex Pharma Down 5% After INCIVEK sales disappoint. - Benzinga 02.03.12 | 01:02 pm
- Incivek Catalyst at Play for Vertex - Analyst Blog - Zacks 02.03.12 | 10:02 am
- Company News for February 1, 2012 - Corporate Summary - Zacks 02.01.12 | 10:02 am
- Vertex Pharma's Latest FDA Approval Is Only The Beginning - Seeking Alpha 02.01.12 | 09:02 am
- Vertex Pharma Surging on FDA Approval - Benzinga 01.31.12 | 01:01 pm
- Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012 - Seeking Alpha 01.27.12 | 09:01 am
- 2 Stocks To Watch, And What's Next For The Market - Seeking Alpha 01.20.12 | 05:01 pm
- The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Inhibitex, Vertex Pharmaceuticals and Merck - Press Releases - Zacks 01.20.12 | 09:01 am
- Market Weekly Outlook: Earnings, Europe, Data ... Oh My? - Seeking Alpha 01.17.12 | 08:01 am
- Biotech Stocks On A Tear: I Like Celgene - Seeking Alpha 01.13.12 | 09:01 am
